Multiple Myeloma Coverage from Every Angle

Eileen M. Boyle, MD, PhD, on Predicting Treatment Response With Genomic and Immune Microenvironment Features in Multiple Myeloma

Posted: Sunday, December 11, 2022

Eileen M. Boyle, MD, PhD, of the Perlmutter Cancer Center, NYU Langone Health, discusses the key factors contributing to sustained remission when patients with newly diagnosed multiple myeloma are treated with immunotherapy and the clinical implications with regard to enhancing responses to therapy.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.